Prolonged response to pemetrexed-based chemotherapy in a patient with peritoneal mesothelioma: A case report and review of the literature

0Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Peritoneal mesothelioma is a rare tumor typically presenting with ascites and associated with occupational asbestos exposure with a latency period of 20-40 years. Intensive multi-modality approach combining cytoreductive surgery, intraperitoneal chemotherapy and possibly radiotherapy can be considered, but otherwise the prognosis is rather poor. Palliative chemotherapy may be an option in these rare cases. However, no approved systemic treatment exists for peritoneal mesothelioma. We present here a patient with peritoneal mesothelioma who was treated with the combination of pemetrexed with cisplatin shortly after the failure of hyperthermic intraperitoneal chemotherapy. The patient experienced durable partial response to the treatment, resolution of ascites, and returned to his normal daily life activities. With the exception of palliative chemotherapy in case of patients in good condition, therapeutic options in patients with peritoneal mesothelioma are currently very limited. The combination of pemetrexed and cisplatin can lead to long-term control in selected patients.

Cite

CITATION STYLE

APA

Studentova, H., Vitásková, D., Čtvrtlík, F., Melichar, B., & Havlík, R. (2016). Prolonged response to pemetrexed-based chemotherapy in a patient with peritoneal mesothelioma: A case report and review of the literature. Pteridines, 27(1–2), 1–5. https://doi.org/10.1515/pterid-2015-0015

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free